Alnylam officer proposes $399K sale of 1,758 shares

The securities information lists 133,809,118 shares outstanding alongside the proposed sale.

Rhea-AI Filing Summary

Alnylam Pharmaceuticals, Inc. (ALNY) reported a proposed sale by officer Bryan A. Supran of 1,758 common shares, with an aggregate market value of $398,862.25, for approximately October 2, 2026. Fidelity Brokerage Services LLC is listed as broker, and Nasdaq as the exchange.

The shares are identified as acquired through restricted-stock vesting on October 1, 2026. The remarks state the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.

Key Figures

Shares proposed for sale: 1,758 shares Aggregate market value: $398,862.25 Approximate sale date: October 2, 2026 +2 more

5 metrics

Shares proposed for sale 1,758 shares Common shares reported for sale by Bryan A. Supran.

Aggregate market value $398,862.25 For the proposed sale.

Approximate sale date October 2, 2026 Date listed for the proposed sale.

Shares outstanding 133,809,118 shares Issuer share count listed in the securities information.

Restricted-stock vesting date October 1, 2026 Date associated with the shares' acquisition.

Key Terms

Restricted Stock Vesting, aggregate market value, vested equity award distribution

3 terms

Restricted Stock Vesting financial

"Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

vested equity award distribution financial

"settlement of a vested equity award distribution"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALNY shares is Bryan A. Supran reporting for sale?

Bryan A. Supran reported a proposed sale of 1,758 ALNY common shares with an aggregate market value of $398,862.25. The approximate sale date is October 2, 2026; Fidelity Brokerage Services LLC and Nasdaq are listed in the sale information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 03:46 PM Accepted by SEC EDGAR 10/02/2026 - 03:45 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001511797
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ALNYLAM PHARMACEUTICALS, INC.
SEC File Number	001-36407
Address of Issuer	675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MASSACHUSETTS 02142
Phone	(617) 551-8200
Name of Person for Whose Account the Securities are To Be Sold	SUPRAN BRYAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1758	398862.25	133809118	10/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2026	Restricted Stock Vesting	Issuer			1758	10/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	10/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jessica Spraker, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Bryan A. Supran.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)